Global Crohn's Disease Market and Forecast Analysis 2017-2035: Number of Prevalent Cases of Crohn's Disease is Expected to Increase by 16.9% to 1.6 Million over 2015-35 - Research and Markets

News provided by

Research and Markets

19 May, 2017, 13:00 BST

DUBLIN, May 19, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Crohn's Disease Market and Forecast Analysis" report to their offering.

Crohn's disease involves inflammation of the gastrointestinal (GI) tract and most commonly affects the terminal ileum or colon. Because Crohn's disease can occur in various areas of the GI tract, disease activity and severity can vary widely over time, with symptoms ranging from mild to severe and depending on the location in the GI tract at which the disease is active. Crohn's disease is a chronic, incurable disease with low mortality that is generally diagnosed in adolescence and early adulthood.

Crohn's disease is currently an idiopathic condition, the pathogenesis of which is yet to be fully elucidated. However, it is known to involve an interaction between genetics, the immune system, and environmental factors. Risk factors include ethnicity, smoking, family history, antibiotic or non-steroidal anti-inflammatory agent use, and diet.

It is estimated that in 2015, there were 1.4 million diagnosed prevalent cases of Crohn's disease in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). Over 2015-35, the number of prevalent cases is expected to increase by 16.9% to 1.6 million.

Key Topics Covered:

1. Treatment: Crohn's Disease

  • Patient Segmentation
  • Current Treatment Options
  • Prescribing Trends
  • Compliance
  • Unmet Needs in Crohn's Disease
  • Prescribing Influences
  • Impact of Biosimilars

2. Epidemiology: Crohn's Disease

  • Disease Background
  • Sources and Methodology
  • Forecast
  • Epidemiologist Insight
  • Strengths and Limitations

3. Marketed Drugs: Crohn's Disease

  • Product profile: Cimzia
  • Product profile: Entyvio
  • Product profile: Humira
  • Product profile: Pentasa
  • Product profile: Remicade
  • Product profile: Tysabri

4. Pipeline: Crohn's Disease

  • Executive Summary
  • Clinical Pipeline Overview

For more information about this report visit http://www.researchandmarkets.com/research/np84nl/crohns_disease

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets